Filing Flows › Macrogenics (MGNX) › Q2 2025
Macrogenics (MGNX) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 14, 2025
Macrogenics (MGNX) reported revenue of $22.2M for the second quarter 2025 (Q2 2025), +106% from a year earlier and +69% from the quarter before. Operating margin was -165.3%, net loss $36.3M (163.0% of revenue).
Macrogenics, Q2 2025: revenue $22.2M (+106% year over year), operating margin -165.3%, net loss $36.3M, operating cash flow −$47.0M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $22.2M | +69% | +106% |
| Operating profit | −$36.8M | — | — |
| Net earnings | −$36.3M | — | — |
| Operating cash flow | −$47.0M | — | — |
What changed
Revenue was $22.2M in Q2 2025, up 106% year over year and up 69% from the previous quarter.
Operating costs exceeded revenue by $36.8M, an operating margin of -165.3%. Total costs fell 14% while revenue rose 106%. The fastest-growing cost line was Other operating costs (+236%). The quarter ended with a net loss of $36.3M, narrower than the previous quarter's $41.0M loss.
Operating cash flow was −$47.0M. Non-cash charges added back $1.9M of depreciation and amortization and $3.7M of share-based compensation. Working capital and other items used $16.3M. Capital expenditures of $715K exceeded it, leaving free cash flow of −$47.7M.
Questions
What was Macrogenics' revenue in the second quarter 2025?
Macrogenics (MGNX) reported revenue of $22.2M for the second quarter 2025 (Q2 2025), +106% from a year earlier and +69% from the quarter before.
Was Macrogenics profitable in the second quarter 2025?
Operating loss was $36.8M (-165.3% of revenue) and net loss $36.3M.
Source: Macrogenics 10-Q on SEC EDGAR.